Biberach, Germany

Gerald Jürgen Roth

This inventor holds 1 USPTO granted patent and 6 EPO patents. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2007.


% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gerald Jürgen Roth: Innovator in Medicinal Chemistry

Introduction

Gerald Jürgen Roth is a notable inventor based in Biberach, Germany. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative patent related to cycloalkyl-containing compounds.

Latest Patents

Roth holds a patent for "Cycloalkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments." This invention pertains to cycloalkyl-containing 5-acylindolinones of a specific general formula. The compounds described in the patent exhibit valuable pharmacological properties, especially their ability to inhibit protein kinases, including glycogen synthase kinase (GSK-3). He has 1 patent to his name.

Career Highlights

Throughout his career, Roth has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharma GmbH & Co. KG. His work in these organizations has contributed to advancements in drug development and therapeutic applications.

Collaborations

Roth has collaborated with esteemed colleagues, including Armin Heckel and Stefan Hoerer. These partnerships have fostered innovation and have been instrumental in the development of his patented technologies.

Conclusion

Gerald Jürgen Roth's contributions to medicinal chemistry through his patent and collaborations highlight his role as an innovator in the pharmaceutical field. His work continues to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…